Brain metastasis is a significant cause of morbidity and mortality in multiple cancer 27 types and represents an unmet clinical need. The mechanisms that mediate metastatic 28 cancer growth in the brain parenchyma are largely unknown. Melanoma, which has the 29 highest rate of brain metastasis among common cancer types, is an ideal model to 30 study how cancer cells adapt to the brain parenchyma. We performed unbiased 31 proteomics analysis of melanoma short-term cultures, a novel model for the study of 32 brain metastasis. Intriguingly, we found that proteins implicated in neurodegenerative 33 pathologies are differentially expressed in melanoma cells explanted from brain 34 metastases compared to those derived from extracranial metastases. This raised the 35 exciting hypothesis that molecular pathways implicated in neurodegenerative disorders 36 are critical for metastatic adaptation to the brain. 37
6 second STC, WM-4265-2 BM 22 , also inhibited brain metastasis without significant 141 effects on metastasis to other organs (Extended Data Figure 2h -j) Thus, APP is 142 required for melanoma to colonize the brain but not to metastasize to other organs. 143 144 Amyloid Beta is the form of APP required for melanoma brain metastasis 145 APP can be processed to produce amyloid beta (Ab), a polypeptide heavily implicated 146 in Alzheimer's disease, through sequential cleavage by beta and gamma secretases. 147
Although APP is expressed in a wide variety of normal tissues and tumor types, 148 potential Ab production by cancer cells has never been explored. Therefore, we sought 149 to investigate whether melanoma cells can produce Ab and if so, whether Ab production 150 is altered in BM vs NBM STCs. Using probe specific gamma-secretase assays 23 , we 151 established that melanoma cells can cleave APP with gamma secretase and observed 152 consistently increased cleavage of APP in BM vs paired NBM STCs (Figure 3a ). 153
Notably, increased cleavage of NOTCH, a canonical gamma secretase substrate, was 154 not consistently observed in paired BM vs NBM STCs (Figure 3b ), which suggests a 155 specific association between APP cleavage and brain metastasis. Analysis of 156 melanoma conditioned media demonstrated that melanoma cells are able to produce 157 and secrete Ab, and that Ab secretion is increased in BM relative to paired NBM STCs 158 ( Figure 3c ). Therefore, we posited that Ab is the specific form of APP required for 159 melanoma brain metastasis. 160
161
To test this hypothesis, we asked whether Ab is sufficient to rescue the inhibition of 162 metastasis observed upon APP silencing. We cloned SPA4CT-T43P 24 , a heavily 163 truncated (>75% of APP amino acid sequence removed), mutant form of APP that 164 retains the ability to produce Ab but cannot produce other major cleavage products, 165 such as sAPP-a and sAPP-b (Figure 3d ). The substitution of proline for threonine at 166 position 43 partially inhibits gamma secretase cleavage 25 and prevents excessive Ab 167 generation (Extended Data Figure 3a ,b). We knocked out APP in 12-273 BM STC using 168 CRISPR/Cas9 and reintroduced either APP-770, the major full-length APP isoform 169 expressed in melanoma cells (Extended Data Figure 3c ), or SPA4CT-T43P (Figure 3e) . 170
We confirmed that knockout of APP reduces Ab secretion and that both wild type APP 7 (APP-770) and SPA4CT-T43P are able to rescue Ab secretion to near physiologic 172 levels (Figure 3f ). In-vivo, the loss of brain metastasis observed upon APP knockout 173 was rescued by introduction of either APP-770 or SPA4CT-T43P (Figure 3g,h) , 174 demonstrating that Ab is the form of APP required for melanoma brain metastasis. 175 176 Melanoma-secreted Amyloid Beta is required for late growth and survival in the 177 brain parenchyma 178
To investigate how Ab functions in melanoma brain metastasis, we began by identifying 179 which step of the brain metastatic process Ab is required for. First, we established the 180 timeline of brain metastasis in 12-273 BM STC by ex-vivo immunofluorescence analysis 181 of brain slices (Figure 4a upper panels, Supplementary Videos 2-6. At day 1 post 182 intracardiac injection, melanoma cells are arrested in the brain microvasculature. By day 183 3, melanoma cells have extravasated into the parenchyma and remain adhered to the 184 surface of blood vessels with a rounded morphology. From days 3 to 7, cells begin to 185 divide and spread along the vasculature in an elongated morphology, a process known 186 as vascular co-option 8 . By day 7, approximately two thirds of the melanoma cells that 187 had initially reached the brain at day 1 have died. This occurs when melanoma cells 188 either fail to extravasate (Figure 4c ) or undergo apoptosis upon entering the brain 189 parenchyma (Figure 4d ). From days 7-14, surviving melanoma cells begin to proliferate 190 in a rounded morphology independent of the vasculature to form micro-metastases. 191
After day 14, cells rapidly divide, forming small macro-metastases visible to the naked 192 eye by day 21. 193 194 When comparing melanoma cells with and without Ab, we did not observe differences in 195 the number of live cells from day 1 through day 7 post intracardiac injection (Figure 4b) , 196
indicating that Ab is not required for vascular arrest, extravasation, or early survival of 197 melanoma cells in the brain parenchyma. Melanoma cells lacking Ab, however, were 198 unable to successfully proliferate to form micro-and macro-metastases by days 14 and 199 21 respectively (Figure 4b ), and instead underwent apoptosis (Extended Data Figure  200 4a). Therefore, Ab is required for melanoma cells to progress from vascular co-option to 201 successful metastatic colonization of the brain parenchyma. 202 surrounding melanoma cells lacking Ab exhibited a more ameboid morphology ( Figure  263 5h), which signifies increased microglial activation 42 . Furthermore, we observed a 264 significantly increase in microglial phagocytosis of melanoma cells lacking Ab (Figure 5i , 265
Extended data Figure 4c , and Supplementary Video 8), demonstrating that Ab secretion 266 protects melanoma cells from phagocytic clearance by microglia. 267 268
Ab is a Promising Therapeutic Target for Treatment of Brain Metastasis 269
To assess if targeting Ab could be a promising therapeutic strategy for treatment of 270 melanoma brain metastasis, we investigated whether Ab is required for growth and 271 survival of established brain metastases. Using a doxycycline inducible shRNA system, 272
we depleted APP in growing melanoma brain macro-metastases (Extended data Figure  273 5a; Figure 6a ). Loss of ability to produce Ab in pre-existing brain metastases resulted in 274 decreased brain metastatic burden (Figure 6b Identifying and characterizing mechanisms that mediate survival of cancer cells in the 289 brain parenchyma has been historically challenging. The majority of studies aiming to 290 identify mechanisms of brain metastasis have utilized cell lines originally derived from 291 extracranial metastases and examined transcriptomic changes after serial 292 transplantation in mice to increase brain tropism 12,46-48 . While these models have been 293 an invaluable tool, the process by which they are generated varies greatly from the 294 brain metastatic process occurring in patients 49 . In contrast, STC pairs exhibiting 295 differential brain tropism ( Figure 1b-d and Extended data fig. 1a ,b) are derived directly 296 from naturally arising metastases in patients 50 . Recently, some studies have directly 297 profiled gene expression of surgically resected patient tumors 19, 51 . While this method 298 has several advantages, such as strong clinical relevance and ability to capture effects 299 mediated by the brain microenvironment, the limited amount of material available per 300 sample can restrict the type of analyses that are technically feasible. Furthermore, direct 301 use of patient biopsies makes it difficult to establish whether genes identified as 302 upregulated in CNS metastases represent contamination from brain tissue or neural 303 mimicry by cancer cells. Proteomic screening of short term cultures -which no longer 304 contain normal brain tissue -circumvents this issue and allowed us to identify an 305 association between brain metastasis and proteins implicated in Alzheimer's disease. 306
307
Several studies have demonstrated that reactive astrocytes support the formation of 308 brain metastasis 10,11 , provided early antagonistic interactions can be overcome 12 . 309
Here, we show that Ab secreted by melanoma cells stimulates astrocytes to exhibit a 310 pro-metastatic, anti-inflammatory phenotype. It was demonstrated that cancer cells in 311 the brain induce a subpopulation of pro-metastatic Stat3 positive reactive astrocytes in 312 their microenvironment by an unknown mechanism 52 . In addition, Stat3 + reactive 313 astrocytes contribute to the pathology of acute brain injury and several 314 neurodegenerative diseases, including Alzheimer's disease. Further investigation is 315 warranted to address whether melanoma-secreted Ab specifically induces Stat3 316 activation in astrocytes. 317
318
Astrocytes have been shown to regulate microglial activity in response to inflammatory 319 insults 53 . A similar role for astrocytes has been theorized in the brain metastatic 320 microenvironment but remains largely unexplored 54 . Here, we establish that melanoma-321 secreted Ab directly suppresses astrocyte secretion of several cytokines that recruit and 322 activate microglia, such as CCL2, a potent chemoattractant that polarizes microglia to a 323 pro-inflammatory, anti-tumorigenic M1 phenotype 41 . Furthermore, we demonstrate that 324 melanoma-secreted Ab inhibits microglial phagocytosis of melanoma cells. Taken 325 together, these results suggest that astrocytes regulate microglial activity in the brain 326 metastatic microenvironment. It is also possible that melanoma-secreted Ab impacts 327 microglial response to melanoma cells directly. A recent study showed that acute 328 exposure to Ab initially stimulated microglial phagocytosis of microparticles, but re-329 exposure of the same microglia to Ab days later instead inhibited phagocytosis 55 . Given 330 the high Ab concentrations used and lack of a continuous exposure of microglia to Ab, it 331
is difficult to interpret that study's findings in the context of the brain metastatic 332 microenvironment. Additional studies are needed to clarify whether melanoma-secreted 333
Ab directly impacts microglial function. Our studies show Ab is a highly promising therapeutic target for melanoma brain 356 metastasis. The brain represents an immune privileged environment and is often a site 357 of treatment resistance or relapse in patients 4 . Although checkpoint blockade 358 immunotherapy, the standard-of-care for metastatic melanoma, can be efficacious in 359 brain metastasis, the rates of on-treatment progression are higher for intracranial than 360 for extracranial metastases 5 . Targeting Ab, which suppresses neuroinflammation, in 361 combination with immune checkpoint inhibitors could result in a more robust anti-tumor 362 immune response and improve patient outcomes. Several therapeutic agents targeting 363
Ab have been developed and extensively tested in clinical trials for treatment of 364
Alzheimer's disease and could be repurposed for treatment of melanoma brain 365 metastasis. One possibility includes BACE small molecule inhibitors, exemplified by 366 LY2886721, which provided proof-of-principle efficacy in our preclinical models. Another 367 attractive approach is the use of anti-Ab antibodies, which have been extensively tested 368 in clinical trials for Alzheimer's disease. Anti-Ab antibodies successfully sequestered Ab 369 in Alzheimer's patients 60 but lacked clinical efficacy 61 . In Phase III clinical trials, anti-370
Ab antibodies were tolerated at high doses for extended periods of time without an 371 increase in rates of adverse effects over placebo 61 . Given that dose limiting toxicities 372 and adverse effects are major drivers of failure in cancer clinical trials, targeting Ab in 373 melanoma brain metastasis with anti-Ab antibodies represents a particularly promising 374 treatment strategy. 375
376
In summary, our studies reveal an unexpected role for tumor-secreted Ab, a polypeptide 377 heavily implicated in Alzheimer's disease, in the adaptation of melanoma cells to the 378 brain microenvironment and provide proof-of-principle of Ab targeting as a novel 379 therapeutic avenue against this devastating condition. Immediately before plating, the astrocyte trophic factor Heparin-binding EGF-like growth 448 factor (HBEGF) was added (5 ng/mL) and media equilibrated to 37°C in a 10% CO2 449 incubator). Cells were incubated at 37°C in 10% CO2. Media was changed (50% well 450 volume) once per week. Trimmed sequences were mapped to mm10 using STAR v2.6.0a 66 , indexed using 480 samtools v1.9 67 , then quantified for UCSC genes using HTSeq-count v0.11.1 68 . 481 The reaction was allowed to proceed for 60 min at room temperature and then 522 quenched using 8 μL of 5% (w/v) hydroxylamine. The samples were combined at a 1:1 523 ratio and the pooled sample was subsequently desalted using strong-cation exchange 524 and strong-anion exchange solid-phase extraction columns (Strata, Phenomenex) as 525 TMT-labeled N-term and lysine, acetylation (protein N-term) and deamidation 557 (asparagine and glutamine) were selected as variable modifications, and 558 carbamidomethyl (C) as fixed modifications; precursor mass tolerance was set to 559 10 ppm; fragment mass tolerance was set to 0.01 Th. The identifications were filtered 560 using a false-discovery rate (FDR) of 0.01 using a target-decoy approach at the protein 561 and peptide level. Only unique peptides were used for quantification and only proteins 562 with at least two unique peptides were reported. Data analysis was performed using 563
Perseus. Protein levels were median centered and log2 normalized. To identify proteins 564 differentially expressed proteins between the BM and NBM cohorts, a Welch's t-test 565 20 was performed between unpaired 14 BM and 11 NBM unpaired samples and a paired t-566 test was performed on the 3 sample pairs. Top differentially expressed genes (defined 567 here as p-value < 0.05) were assessed at the pathway level using DAVID GO-term 568 enrichment with an FDR < 0.001 (ref) . 569 570
Animal Studies 571
All experiments were conducted following protocols approved by the NYU Institutional 572
Animal Care Use Committee (IACUC) (protocol number s16-00051). NOD/SCID/IL2yR -/-573 male mice (Jackson Labs, Cat# 05557) at 6-8 weeks were used for in-vivo studies. For all long-term brain metastasis assays, 12 mice per group underwent intracardiac 585 injection with cancer cells. Experimental group sizes vary from 10 to 12 mice due to 586 infrequent instances of unsuccessful intracardiac injection. 587
588
In-vivo BLI. 10 minutes prior to imaging, luciferin substrate (150mg/kg) was 589 administered to mice by intraperitoneal injection. Mice were anesthetized with isoflurane 590 and imaged by IVIS Illumina instrument (PerkinElmer) for an automatically-determined 591 duration (1-120 sec). Signal was quantified by measurement of total luminescent flux 592 (p/sec/cm 2 /sr) in drawn brain and body regions of interest. 593 incision was made in the right atrium. Subsequently, 10 mL of PBS followed by 10 mL of 597 4% PFA was injected into the left ventricle. 598 599 Short-term brain metastasis assays and brain slice immunofluorescence. 1x10 5 (for live 600 melanoma cell quantification) or 5 x 10 5 (for astrocyte and microglial scoring) 12-273 BM Drug treatment experiments. Protocol for long-term brain metastasis assay (as 608 described above) was performed. LY288671 (75mg/kg/day) was administered to mice in 609 food pellets starting one week prior to intracardiac injection of cancer cells and 610 continuing through the experimental endpoint. 611
612
Continuous shRNA-mediated gene silencing. Protocol for long-term brain metastasis 613 assay (as described above) was performed. Doxycycline hyclate (200mg/kg/day) was 614 administered to mice in food pellets starting two days prior to intracardiac injection of 615 cancer cells and continuing for the experimental duration. 616 617 Induction of gene silencing in growing metastases. Protocol for long-term brain 618 metastasis assay (as described above) was performed. Mice were administered a 619 normal diet at the beginning of the experiment. 21 days after intracardiac injection of 620 cancer cells, gene silencing was induced by administration of Doxycycline hyclate 621 (200mg/kg/day) in food pellets. 622 623
Mouse tissue processing, histology and NuMA Immunohistochemistry 624
Organs harvested from PFA-perfused mice were fixed in 10% formalin for 48 hours. 625
Prior to embedding, brains were sectioned grossly into thirds coronally and livers were 626 sectioned by lobe. Organs were embedded in paraffin and cut into 5uM thick sections. 627 24 690
Astrocyte + Microglia Scoring 691
Confocal (microglia) or non-confocal (astrocyte) images were captured randomly of live 692 cancer cells and their surrounding brain parenchyma. Blinded images were scored 693 according to a qualitative scoring system. For astrocytes, the criteria used to assign a 694 score of 0-4 were brighter GFAP staining than nearby brain parenchyma, extent of 695 astrocyte branching, and extent of GFAP interaction with cancer cells (see Extended 696
Data Figure 4b for example score images). For microglia, the criteria used to assign a 697 score of 0-3 were reactive morphology (less ramified, more ameboid) 42 pLVX was digested with XhoI and NotI and religated together with the two inserts. For 784 specific sequences, see Extended Data Table 2 . SPA4CT-T43P was generated using 785 the Q5 Site-Directed Mutagenesis Kit (NEB E0554S) using pLVX SPA4CT as a 786 template. For specific sequences of primers and inserts, please see Extended Data 787 Table 2 . In-vitro Proliferation Assay 804 2 days prior to assay, genetic silencing was induced by addition of doxycycline (1 805 ug/mL) to media. 1 x 10 4 12-273 BM or 1 x 10 4 WM-4265 BM cells were plated in four 806 24-well plates. After allowing cells to adhere overnight, a baseline plate was obtained by 807 removal of media and fixation in .1% glutaraldehyde for 15 minutes. Remaining plates 808 were fixed every 24 hours thereafter. Wells were stained with .5% crystal violet in PBS 809
for one hour and washed extensively with water. Crystal violet retained by cells was 810 then eluted by incubation in 250uL 15% acetic acid for 1 hour with shaking. 100uL from 811 each well was transferred to a 96 well plate and absorbance at 590 nm was measured. 812
